Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma

.....T his is the first case of PRES during ipilimumab therapy. Increasing awareness of PRES is needed in patients who undergo anti–CTLA-4 therapies and develop irAEs such as hypophysitis in our patient. Autoimmune disorders are associated with an increased risk of PRES; autoimmune hypophysitis, however, does not seem to be implicated in the development of PRES. Further inves- tigations on the mechanisms of toxicity and risk factors for PRES are necessary

Data di pubblicazione: 2012
Titolo: Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma
Autori: Maur, Michela; Tomasello, Chiara; Frassoldati, Antonio; Dieci, Maria Vittoria; Barbieri, Elena; Conte, Pierfranco
Rivista: JOURNAL OF CLINICAL ONCOLOGY
Parole Chiave: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Melanoma; Middle Aged; Posterior Leukoencephalopathy Syndrome; Skin Neoplasms; Vaginal Neoplasms; Cancer Research; Oncology
Abstract in inglese: .....T his is the first case of PRES during ipilimumab therapy. Increasing awareness of PRES is needed in patients who undergo anti–CTLA-4 therapies and develop irAEs such as hypophysitis in our patient. Autoimmune disorders are associated with an increased risk of PRES; autoimmune hypophysitis, however, does not seem to be implicated in the development of PRES. Further inves- tigations on the mechanisms of toxicity and risk factors for PRES are necessary
Digital Object Identifier (DOI): 10.1200/JCO.2011.38.7886
Handle: http://hdl.handle.net/11392/2377819
Appare nelle tipologie:03.1 Articolo su rivista

File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2022